|
|
| (One intermediate revision not shown.) |
| Line 3: |
Line 3: |
| | <StructureSection load='6phg' size='340' side='right'caption='[[6phg]], [[Resolution|resolution]] 2.00Å' scene=''> | | <StructureSection load='6phg' size='340' side='right'caption='[[6phg]], [[Resolution|resolution]] 2.00Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6phg]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PHG OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PHG FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6phg]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PHG OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6PHG FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6phb|6phb]]</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6phg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6phg OCA], [http://pdbe.org/6phg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6phg RCSB], [http://www.ebi.ac.uk/pdbsum/6phg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6phg ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6phg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6phg OCA], [https://pdbe.org/6phg PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6phg RCSB], [https://www.ebi.ac.uk/pdbsum/6phg PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6phg ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| Line 17: |
Line 17: |
| | </div> | | </div> |
| | <div class="pdbe-citations 6phg" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 6phg" style="background-color:#fffaf0;"></div> |
| | + | |
| | + | ==See Also== |
| | + | *[[Antibody 3D structures|Antibody 3D structures]] |
| | + | *[[Sandbox 20009|Sandbox 20009]] |
| | + | *[[3D structures of human antibody|3D structures of human antibody]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Julien, J P]] | + | [[Category: Julien JP]] |
| - | [[Category: McLeod, B R]] | + | [[Category: McLeod BR]] |
| - | [[Category: Antigen]]
| + | |
| - | [[Category: Complex]]
| + | |
| - | [[Category: Fab]]
| + | |
| - | [[Category: Immune system]]
| + | |
| - | [[Category: Immunoglobulin]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Transmission-blocking vaccines have the potential to be key contributors to malaria elimination. Such vaccines elicit antibodies that inhibit parasites during their development in Anopheles mosquitoes, thus breaking the cycle of transmission. To date, characterization of humoral responses to Plasmodium falciparum transmission-blocking vaccine candidate Pfs25 has largely been conducted in pre-clinical models. Here, we present molecular analyses of human antibody responses generated in a clinical trial evaluating Pfs25 vaccination. From a collection of monoclonal antibodies with transmission-blocking activity, we identify the most potent transmission-blocking antibody yet described against Pfs25; 2544. The interactions of 2544 and three other antibodies with Pfs25 are analyzed by crystallography to understand structural requirements for elicitation of human transmission-blocking responses. Our analyses provide insights into Pfs25 immunogenicity and epitope potency, and detail an affinity maturation pathway for a potent transmission-blocking antibody in humans. Our findings can be employed to guide the design of improved malaria transmission-blocking vaccines.
Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.,McLeod B, Miura K, Scally SW, Bosch A, Nguyen N, Shin H, Kim D, Volkmuth W, Ramisch S, Chichester JA, Streatfield S, Woods C, Schief WR, Emerling D, King CR, Julien JP Nat Commun. 2019 Sep 24;10(1):4328. doi: 10.1038/s41467-019-11980-6. PMID:31551421[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ McLeod B, Miura K, Scally SW, Bosch A, Nguyen N, Shin H, Kim D, Volkmuth W, Ramisch S, Chichester JA, Streatfield S, Woods C, Schief WR, Emerling D, King CR, Julien JP. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25. Nat Commun. 2019 Sep 24;10(1):4328. doi: 10.1038/s41467-019-11980-6. PMID:31551421 doi:http://dx.doi.org/10.1038/s41467-019-11980-6
|
